This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The two trials used were international, multicentre, randomised and double-blind. They included women with metastatic breast cancer with one or more osteolytic lesions at least 1cm in diameter.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
The authors used the two trials to gain approval for pamidronate from the United States Food and Drug Administration.
Methods used to judge relevance and validity, and for extracting data
See previous comment.
Number of primary studies included
Two primary studies were included.
Methods of combining primary studies
The trials used were parallel studies differentiated by whether the patient received hormonal therapy or chemotherapy as their systemic treatment. These studies were not combined but were analysed separately.
Investigation of differences between primary studies
As part of the sensitivity analyses, the results were pooled. This was justified with reference to the results of a study that found no significant difference in the odds ratio of having a SRE between recipients of hormonal therapy or chemotherapy. The authors acknowledged that the number need to treat to prevent an SRE did differ between the two studies and that this weakened the case for pooling the data in a cost-effectiveness study.
Results of the review
The median survival for chemotherapy patients was 14.8 months on pamidronate versus 14.0 months on placebo; for hormonal patients the corresponding results were 23.2 months and 23.5 months.
The total number of SREs (presumably over a 24 month period) in the chemotherapy trial was 387 for patients on pamidronate versus 630 for patients on placebo. The corresponding numbers for hormonal patients were 475 and 627. This includes a high percentage of fractures not requiring surgery.
In the chemotherapy trial there were 251 fractures among patients on pamidronate versus 349 for patients on placebo. In the hormonal trial, the corresponding numbers were 331 versus 403.
In the chemotherapy trial, 105 courses of radiotherapy were given in the pamidronate group versus 207 courses in the placebo group. In the hormonal trial 114 versus 192 courses were given.
Methods used to derive estimates of effectiveness
The authors made various assumptions to complete their model, some of which were relaxed or changed using sensitivity analysis.
